AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 7974297 — intervention group
Group type: EXPERIMENTAL
Intervention: Nedocromil sodium
Number of subjects: 54
Study 2690044 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone 100 mg daily
Number of subjects: 0
Study 2690044 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 4442386 — intervention group
Group type: EXPERIMENTAL
Intervention: Preloaded with glucose under 50 dBA noise (Group A)
Number of subjects: 32
Study 4442386 — intervention group
Group type: EXPERIMENTAL
Intervention: Preloaded with glucose under 80 dBA noise (Group B)
Number of subjects: 32
Study 4442386 — intervention group
Group type: COMPARATOR
Intervention: Not preloaded with glucose under 80 dBA noise (Group C)
Number of subjects: 32
Study 4442386 — intervention group
Group type: COMPARATOR
Intervention: Not preloaded with glucose under 50 dBA noise (Group D)
Number of subjects: 32
Study 29429455 — intervention group
Group type: EXPERIMENTAL
Intervention: Rehabilitation intervention (early rehabilitation including oral sensory and muscle strength training, pressure touching of head, chest, abdomen, extremities, hands, and feet)
Number of subjects: 97
Study 29429455 — intervention group
Group type: EXPERIMENTAL
Intervention: Rehabilitation intervention
Number of subjects: 97
Study 29429455 — intervention group
Group type: COMPARATOR
Intervention: Control group (no early rehabilitation intervention)
Number of subjects: 97
Study 29429455 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 97
Study 28078678 — intervention group
Group type: EXPERIMENTAL
Intervention: Ingenol disoxate 0.037%
Number of subjects: 0
Study 28078678 — intervention group
Group type: EXPERIMENTAL
Intervention: Ingenol disoxate 0.05%
Number of subjects: 0
Study 28078678 — intervention group
Group type: COMPARATOR
Intervention: Vehicle gel
Number of subjects: 0
Study 28078678 — intervention group
Group type: EXPERIMENTAL
Intervention: Ingenol disoxate 0.037% and 0.05%
Number of subjects: 0
Study 23153049 — intervention group
Group type: EXPERIMENTAL
Intervention: Straight injection (SI)
Number of subjects: 105
Study 23153049 — intervention group
Group type: EXPERIMENTAL
Intervention: Oblique injection (OI)
Number of subjects: 105
Study 23153049 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-plane tunnel injection (DPTI)
Number of subjects: 105
Study 21509582 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral patient education
Number of subjects: 3541
Study 21509582 — intervention group
Group type: COMPARATOR
Intervention: Patient education (control)
Number of subjects: 3541
Study 18048583 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypobaric hypoxia (simulated altitude of 4,000-5,500 m)
Number of subjects: 23
Study 18048583 — intervention group
Group type: COMPARATOR
Intervention: Normobaric normoxia (0-500 m)
Number of subjects: 23
Study 18048583 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypobaric hypoxia
Number of subjects: 23
Study 18048583 — intervention group
Group type: COMPARATOR
Intervention: Normobaric normoxia
Number of subjects: 23
Study 17066740 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Number of subjects: 40
Study 17066740 — intervention group
Group type: COMPARATOR
Intervention: Azathioprine
Number of subjects: 40
Study 17066740 — intervention group
Group type: COMPARATOR
Intervention: Plasma exchange
Number of subjects: 40
Study 17066740 — intervention group
Group type: COMPARATOR
Intervention: Methylprednisolone
Number of subjects: 40
Study 17066740 — intervention group
Group type: COMPARATOR
Intervention: Daily oral cyclophosphamide
Number of subjects: 40
Study 17066740 — intervention group
Group type: COMPARATOR
Intervention: Pulse cyclophosphamide
Number of subjects: 40
Study 15815120 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta blocker intervention (n=124)
Number of subjects: 359
Study 15815120 — intervention group
Group type: EXPERIMENTAL
Intervention: Internal mammary artery grafting intervention (n=114)
Number of subjects: 359
Study 15815120 — intervention group
Group type: COMPARATOR
Intervention: Lower volume IMA sites
Number of subjects: 359
Study 11752510 — intervention group
Group type: EXPERIMENTAL
Intervention: Willow bark extract (Assalix) - 240 mg of salicin daily
Number of subjects: 228
Study 11752510 — intervention group
Group type: COMPARATOR
Intervention: Rofecoxib - 12.5 mg daily
Number of subjects: 228
Study 9436672 — intervention group
Group type: EXPERIMENTAL
Intervention: Small diameter laparoscopy (SDL)
Number of subjects: 37
Study 9436672 — intervention group
Group type: COMPARATOR
Intervention: Conventional laparoscopy (CL)
Number of subjects: 37
Study 8099808 — intervention group
Group type: EXPERIMENTAL
Intervention: Amino acid infusion
Number of subjects: 8
Study 8099808 — intervention group
Group type: COMPARATOR
Intervention: Matched control patients
Number of subjects: 8
Study 3240887 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g oxytetracycline hydrochloride
Number of subjects: 78
Study 3240887 — intervention group
Group type: COMPARATOR
Intervention: Hypertonic saline
Number of subjects: 78
Study 3240887 — intervention group
Group type: COMPARATOR
Intervention: Prostaglandin F2 alpha
Number of subjects: 78
Study 3240887 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of oxytetracycline hydrochloride with hypertonic saline and prostaglandin F2 alpha
Number of subjects: 78
Study 31787026 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based exercise with telemonitoring guidance (30 patients)
Number of subjects: 90
Study 31787026 — intervention group
Group type: EXPERIMENTAL
Intervention: Centre-based exercise (30 patients)
Number of subjects: 90
Study 31787026 — intervention group
Group type: COMPARATOR
Intervention: Control group (30 patients)
Number of subjects: 90
Study 31787026 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (Home-based, Centre-based, Control)
Number of subjects: 90
Study 29898671 — intervention group
Group type: EXPERIMENTAL
Intervention: Sit-to-stand exercise performed at four occasions daily and a protein-rich oral supplement, twice a day for 12 weeks.
Number of subjects: 120
Study 29898671 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control group).
Number of subjects: 120
Study 28886394 — intervention group
Group type: EXPERIMENTAL
Intervention: Challenging fat talk vignette
Number of subjects: 283
Study 28886394 — intervention group
Group type: COMPARATOR
Intervention: Fat talk vignette
Number of subjects: 283
Study 25115659 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrusion force of 60 g applied for 21 days on experimental group premolars
Number of subjects: 17
Study 25115659 — intervention group
Group type: COMPARATOR
Intervention: Control group (no force applied)
Number of subjects: 17
Study 22261129 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple doses of misoprostol (400 μg every 6 hours, up to 4 doses)
Number of subjects: 120
Study 22261129 — intervention group
Group type: COMPARATOR
Intervention: Misoprostol plus oxytocin (initial 600 μg vaginal misoprostol followed by intravenous oxytocin)
Number of subjects: 120
Study 20309628 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide-containing adjuvant chemotherapy
Number of subjects: 458
Study 20309628 — intervention group
Group type: COMPARATOR
Intervention: No adjuvant therapy
Number of subjects: 458
Study 17376252 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil-sevoflurane
Number of subjects: 44
Study 17376252 — intervention group
Group type: COMPARATOR
Intervention: Remifentanil-propofol
Number of subjects: 44
Study 17376252 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 44
Study 15636620 — intervention group
Group type: EXPERIMENTAL
Intervention: Composition of four LAB and four fibers
Number of subjects: 66
Study 15636620 — intervention group
Group type: COMPARATOR
Intervention: Fibers only
Number of subjects: 66
Study 12076912 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation + 20 mg IV doxorubicin (Doxil) 24 hr before ablation
Number of subjects: 10
Study 12076912 — intervention group
Group type: COMPARATOR
Intervention: Radiofrequency ablation alone
Number of subjects: 10
Study 12076912 — intervention group
Group type: COMPARATOR
Intervention: Control lesions (unablated)
Number of subjects: 10
Study 10388382 — intervention group
Group type: EXPERIMENTAL
Intervention: Scotchbond Multi‐Purpose/P50 placed in increments
Number of subjects: 48
Study 10388382 — intervention group
Group type: EXPERIMENTAL
Intervention: Scotchbond Multi‐Purpose/P50 placed in bulk
Number of subjects: 48
Study 10388382 — intervention group
Group type: EXPERIMENTAL
Intervention: Clearfil Liner Bond 2/Clearfil Ray Posterior placed in bulk
Number of subjects: 48
Study 8583136 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon alpha 2b therapy at a dose of 5 MU administered daily until a response was achieved (minimum 6 months or maximum 1 year).
Number of subjects: 37
Study 2654215 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical corticosteroid cream applied twice daily until clearing was achieved
Number of subjects: 53
Study 2654215 — intervention group
Group type: COMPARATOR
Intervention: Placebo cream applied twice daily until clearing was achieved
Number of subjects: 53
Study 116053 — intervention group
Group type: EXPERIMENTAL
Intervention: Irrigor (30 to 150 mg daily, administered in tablets, intramuscularly, and intravenously)
Number of subjects: 103
Study 116053 — intervention group
Group type: EXPERIMENTAL
Intervention: Irrigor (administered in courses, single intravenous infusion, double blind method)
Number of subjects: 103
Study 116053 — intervention group
Group type: EXPERIMENTAL
Intervention: Irrigor (administered intramuscularly and intravenously)
Number of subjects: 103
Study 116053 — intervention group
Group type: EXPERIMENTAL
Intervention: Irrigor
Number of subjects: 103
Study 31090434 — intervention group
Group type: EXPERIMENTAL
Intervention: Xiaoaiping injections (1 dose/day for 10 days) with chemotherapy
Number of subjects: 140
Study 31090434 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy only
Number of subjects: 140
Study 28437787 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.6 mL∙kg‐1 of 0.25% levobupivacaine
Number of subjects: 40
Study 28437787 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.8 mL∙kg‐1 of 0.25% levobupivacaine
Number of subjects: 40
Study 28437787 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 mL∙kg‐1 of 0.25% levobupivacaine
Number of subjects: 40
Study 25624379 — intervention group
Group type: EXPERIMENTAL
Intervention: Calories only
Number of subjects: 823
Study 25624379 — intervention group
Group type: EXPERIMENTAL
Intervention: Calories plus minutes
Number of subjects: 823
Study 25624379 — intervention group
Group type: EXPERIMENTAL
Intervention: Calories plus miles
Number of subjects: 823
Study 25624379 — intervention group
Group type: COMPARATOR
Intervention: No labels
Number of subjects: 823
Study 23618131 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical reconstruction
Number of subjects: 6
Study 21323688 — intervention group
Group type: EXPERIMENTAL
Intervention: Dried plums (50 g b.d., fibre=6 gm/day)
Number of subjects: 40
Study 21323688 — intervention group
Group type: COMPARATOR
Intervention: Psyllium (11 g b.d., fibre=6 gm/day)
Number of subjects: 40
Study 19431054 — intervention group
Group type: EXPERIMENTAL
Intervention: Discharge planning (DP)
Number of subjects: 0
Study 17518930 — intervention group
Group type: EXPERIMENTAL
Intervention: Stimulation+support
Number of subjects: 43
Study 17518930 — intervention group
Group type: EXPERIMENTAL
Intervention: Support
Number of subjects: 43
Study 17518930 — intervention group
Group type: EXPERIMENTAL
Intervention: Stimulation
Number of subjects: 43
Study 16636152 — intervention group
Group type: EXPERIMENTAL
Intervention: Community coalitions for asthma control
Number of subjects: 7
Study 16636152 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-wide actions instituted by coalitions
Number of subjects: 7
Study 12915329 — intervention group
Group type: EXPERIMENTAL
Intervention: Replacement of 10% of energy from saturated fats by trans fatty acids
Number of subjects: 0
Study 12915329 — intervention group
Group type: COMPARATOR
Intervention: Replacement of monounsaturated fats by carbohydrates
Number of subjects: 0
Study 12915329 — intervention group
Group type: COMPARATOR
Intervention: Trans fats or saturated fats (acute postprandial effects)
Number of subjects: 0
Study 10618942 — intervention group
Group type: EXPERIMENTAL
Intervention: Esmolol 80 mg i.v.
Number of subjects: 20
Study 10618942 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 8552916 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training programme
Number of subjects: 10
Study 1742224 — intervention group
Group type: EXPERIMENTAL
Intervention: Batanopride (0.2 to 6.0 mg/kg)
Number of subjects: 208
Study 1742224 — intervention group
Group type: EXPERIMENTAL
Intervention: Batanopride (highest dose group)
Number of subjects: 208
Study 1742224 — intervention group
Group type: COMPARATOR
Intervention: Methylprednisolone (250 mg)
Number of subjects: 208
Study 7178821 — intervention group
Group type: EXPERIMENTAL
Intervention: Chenodeoxycholic acid (CDCA) 1000 mg/day
Number of subjects: 8
Study 7178821 — intervention group
Group type: COMPARATOR
Intervention: Ursodeoxycholic acid (UDCA) 1000 mg/day
Number of subjects: 8
Study 31917897 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptive training (N = 30)
Number of subjects: 60
Study 31917897 — intervention group
Group type: EXPERIMENTAL
Intervention: Met allele carriers (part of genetic study)
Number of subjects: 60
Study 31917897 — intervention group
Group type: COMPARATOR
Intervention: Active control group (N = 30)
Number of subjects: 60
Study 30864639 — intervention group
Group type: EXPERIMENTAL
Intervention: α-tocopherol (n=24)
Number of subjects: 71
Study 30864639 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocotrienol-rich fraction (n=24)
Number of subjects: 71
Study 30864639 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=23)
Number of subjects: 71
Study 28167201 — intervention group
Group type: EXPERIMENTAL
Intervention: Iontophoresis-assisted AFL-PDT with 2h incubation (Group A)
Number of subjects: 41
Study 28167201 — intervention group
Group type: COMPARATOR
Intervention: Conventional AFL-PDT with 2h incubation (Group B)
Number of subjects: 41
Study 28167201 — intervention group
Group type: COMPARATOR
Intervention: Conventional AFL-PDT with 3h incubation (Group C)
Number of subjects: 41
Study 28167201 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (A, B, C)
Number of subjects: 41
Study 26640796 — intervention group
Group type: EXPERIMENTAL
Intervention: Customized external strap orthosis
Number of subjects: 9
Study 23143701 — intervention group
Group type: EXPERIMENTAL
Intervention: High frequency/high peak‐to‐peak displacement (HH)
Number of subjects: 223
Study 23143701 — intervention group
Group type: COMPARATOR
Intervention: Low frequency/low peak‐to‐peak displacement (LL)
Number of subjects: 223
Study 23143701 — intervention group
Group type: COMPARATOR
Intervention: Sham intervention (SHAM)
Number of subjects: 223
Study 23143701 — intervention group
Group type: COMPARATOR
Intervention: All groups (HH, LL, SHAM)
Number of subjects: 223
Study 21457066 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin glulisine (GLU)
Number of subjects: 0
Study 21457066 — intervention group
Group type: COMPARATOR
Intervention: Insulin aspart (ASP)
Number of subjects: 0
Study 21457066 — intervention group
Group type: COMPARATOR
Intervention: Insulin lispro (LIS)
Number of subjects: 0
Study 18644678 — intervention group
Group type: EXPERIMENTAL
Intervention: Early luteal phase (progesterone high)
Number of subjects: 9
Study 18644678 — intervention group
Group type: EXPERIMENTAL
Intervention: Ovulatory phase (estrogens high)
Number of subjects: 9
Study 16943370 — intervention group
Group type: EXPERIMENTAL
Intervention: Rizatriptan 5 mg (for body weight 20 to 39 kg)
Number of subjects: 96
Study 16943370 — intervention group
Group type: EXPERIMENTAL
Intervention: Rizatriptan 10 mg (for body weight 40 kg or more)
Number of subjects: 96
Study 16943370 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 96
Study 16943370 — intervention group
Group type: EXPERIMENTAL
Intervention: Rizatriptan 5 mg
Number of subjects: 96
Study 16943370 — intervention group
Group type: EXPERIMENTAL
Intervention: Rizatriptan 10 mg
Number of subjects: 96
Study 16943370 — intervention group
Group type: EXPERIMENTAL
Intervention: Rizatriptan
Number of subjects: 96
Study 12631480 — intervention group
Group type: EXPERIMENTAL
Intervention: ADCON-T/N
Number of subjects: 45
Study 12631480 — intervention group
Group type: COMPARATOR
Intervention: Control (no ADCON-T/N)
Number of subjects: 45
Study 10853305 — intervention group
Group type: EXPERIMENTAL
Intervention: Homozygous sickle cell disease
Number of subjects: 66
Study 10853305 — intervention group
Group type: COMPARATOR
Intervention: Healthy children
Number of subjects: 66
Study 9014635 — intervention group
Group type: EXPERIMENTAL
Intervention: Forced group (Fg) with active warming by a forced air system (n = 10)
Number of subjects: 26
Study 9014635 — intervention group
Group type: COMPARATOR
Intervention: Passive group (Pg) with reflective insulation on all available skin surface (n = 10)
Number of subjects: 26
Study 9014635 — intervention group
Group type: COMPARATOR
Intervention: Reference group (Rg) without a tourniquet (n = 6)
Number of subjects: 26
Study 1389845 — intervention group
Group type: EXPERIMENTAL
Intervention: Org 9426 (rocuronium) 600 micrograms kg‐1 at 60 s
Number of subjects: 20
Study 1389845 — intervention group
Group type: EXPERIMENTAL
Intervention: Org 9426 (rocuronium) 600 micrograms kg‐1 at 90 s
Number of subjects: 20
Study 1389845 — intervention group
Group type: COMPARATOR
Intervention: Suxamethonium 1 mg kg‐1
Number of subjects: 20
Study 1389845 — intervention group
Group type: EXPERIMENTAL
Intervention: Org 9426 (rocuronium)
Number of subjects: 20
Study 2856893 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg oral nadolol o.d.
Number of subjects: 68
Study 2856893 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg oral nadolol o.d.
Number of subjects: 68
Study 2856893 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mg oral nadolol o.d.
Number of subjects: 68
Study 2856893 — intervention group
Group type: COMPARATOR
Intervention: 0.25% topical timolol b.d.
Number of subjects: 68
Study 2856893 — intervention group
Group type: COMPARATOR
Intervention: 0.5% topical timolol b.d.
Number of subjects: 68
Study 2856893 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral nadolol (various doses)
Number of subjects: 68
Study 2856893 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term therapy with oral nadolol
Number of subjects: 68
Study 2856893 — intervention group
Group type: EXPERIMENTAL
Intervention: Nadolol
Number of subjects: 68
Study 31900761 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-regulation group (expressive writing about deepest feelings related to cancer, cognitive reappraisal, and benefit finding over 3 weeks)
Number of subjects: 136
Study 31900761 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced self-regulation group (expressive writing with reversed topics for weeks 1 and 2)
Number of subjects: 136
Study 31900761 — intervention group
Group type: COMPARATOR
Intervention: Cancer-fact group (writing about cancer experiences objectively for 3 weeks)
Number of subjects: 136
Study 29895289 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent IV paracetamol
Number of subjects: 208
Study 29895289 — intervention group
Group type: COMPARATOR
Intervention: Continuous IV morphine
Number of subjects: 208
Study 27619773 — intervention group
Group type: EXPERIMENTAL
Intervention: Corifollitropin alpha (CFA) 150 mg single injection
Number of subjects: 2896
Study 27619773 — intervention group
Group type: COMPARATOR
Intervention: Recombinant FSH (rFSH) 200 IU daily injections (ENGAGE) or 300 IU daily injections (PURSUE)
Number of subjects: 2896
Study 24179986 — intervention group
Group type: EXPERIMENTAL
Intervention: Liner group (firing of 2 layers of paste liner, etched with hydrofluoric acid, treated with silane)
Number of subjects: 120
Study 24179986 — intervention group
Group type: EXPERIMENTAL
Intervention: Glaze group (firing of 2 layers of overglaze, etched with hydrofluoric acid, treated with silane)
Number of subjects: 120
Study 24179986 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocatec group (Rocatec treatment and silane application)
Number of subjects: 120
Study 24179986 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonic-Rocatec group (Rocatec treatment followed by ultrasonic cleaning and silanization)
Number of subjects: 120
Study 24179986 — intervention group
Group type: EXPERIMENTAL
Intervention: Alumina group (sandblasted with alumina)
Number of subjects: 120
Study 24179986 — intervention group
Group type: COMPARATOR
Intervention: Control group (as-sintered with no pretreatment)
Number of subjects: 120
Study 23245940 — intervention group
Group type: EXPERIMENTAL
Intervention: Calendula cream
Number of subjects: 411
Study 23245940 — intervention group
Group type: COMPARATOR
Intervention: Essex cream
Number of subjects: 411
Study 23245940 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 411
Study 21050564 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete intubation group (n=20)
Number of subjects: 40
Study 21050564 — intervention group
Group type: COMPARATOR
Intervention: Partial intubation group (n=20)
Number of subjects: 40
Study 17768173 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciclosporin
Number of subjects: 467
Study 17768173 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone
Number of subjects: 467
Study 17768173 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple therapy (Ciclosporin + Prednisolone)
Number of subjects: 467
Study 17768173 — intervention group
Group type: COMPARATOR
Intervention: Methotrexate
Number of subjects: 467
Study 17221013 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous dipyrone
Number of subjects: 27
Study 17221013 — intervention group
Group type: COMPARATOR
Intervention: Intravenous metoclopramide
Number of subjects: 27
Study 14624420 — intervention group
Group type: EXPERIMENTAL
Intervention: Balloon angioplasty
Number of subjects: 150
Study 14624420 — intervention group
Group type: COMPARATOR
Intervention: Elective Wiktor I stent implantation
Number of subjects: 150
Study 12454761 — intervention group
Group type: EXPERIMENTAL
Intervention: Fulvestrant 250 mg
Number of subjects: 30
Study 12454761 — intervention group
Group type: EXPERIMENTAL
Intervention: Fulvestrant 125 mg
Number of subjects: 30
Study 12454761 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 10379016 — intervention group
Group type: EXPERIMENTAL
Intervention: Soybean oil diet (0.5 g trans fatty acid per 100 g fat)
Number of subjects: 36
Study 10379016 — intervention group
Group type: EXPERIMENTAL
Intervention: Semiliquid margarine diet (0.5 g trans fatty acid per 100 g fat)
Number of subjects: 36